Prestige Consumer Healthcare reported Q3 revenue of $283.4 million, down 2.4%, but expects improvement in supply constraints for Clear Eyes brand through 2026, with revenue guidance narrowed to $1.1 billion. The company closed the Pillar5 acquisition and plans to increase production through 2026. Despite lower sales, profitability metrics were consistent with expectations, and free cash flow increased. Management outlined actions to support growth in eye care, including new suppliers, acquisition of Pillar5, and installation of a high-speed production line. Future focus will be on brand investment and M&A. Analysts expect adjusted diluted EPS of $4.54 for fiscal 2026.

Read more at Yahoo Finance: Prestige Consumer Healthcare Q3 Earnings Call Highlights